Evidence map›Paper›PMID 41857656›Full record

ArticleMolecular brain2026

Central nervous system pericytes express soluble ST2 in inflammation and injury.

Deidre Jansson, Blake Highet, Susan Li, Taylor J Stevenson, Leon C D Smyth, Justin Rustenhoven, Sheryl Feng, Richard Daneman, Cayce Dorrier, Andrew Clarkson and 2 more

Abstract read
In one paragraph

Article in Molecular brain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Deidre JanssonDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand. djj24@uw.edu.
Blake HighetCentre for Brain Research, The University of Auckland, Auckland, New Zealand.
Susan LiDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.
Taylor J StevensonDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.
Leon C D SmythDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.
Justin RustenhovenDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.
Sheryl FengDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.
Richard DanemanDepartment of Neurosciences, Department of Pharmacology, University of California, San Diego, USA.
Cayce DorrierDepartment of Neurosciences, Department of Pharmacology, University of California, San Diego, USA.
Andrew ClarksonDepartment of Anatomy, Brain Health Research Centre and Brain Research New Zealand,, University of Otago, Dunedin, New Zealand.
Emma ScotterCentre for Brain Research, The University of Auckland, Auckland, New Zealand.
Mike DragunowDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand. m.dragunow@auckland.ac.nz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain pericytes are mediators of neuroinflammation, as evidenced in vitro, in animal models and humans. We and others have identified the platelet-derived growth factor (PDGF)-BB -PDGF receptor beta (PDGFRB) pathway as a key modulator of inflammatory cues in human brain pericytes. We investigate the receptor for interkeukin-33 (IL-33), interkeukin-1 receptor-like 1 (IL1RL1; also known as ST2) as a highly upregulated transcript in response to PDGF-BB stimulation in pericyte cultures. We show that pericytes express transcripts for both the membrane bound form of the receptor (ST2L) and the soluble form (sST2) that acts as a decoy and blocks IL-33 signalling. Human brain pericytes secrete sST2 in response to PDGF-BB, but also to transforming growth factor alpha (TGF) alpha and interleukin-4 (IL-4), although they are unresponsive to IL-33 treatment. We also examine pericyte expression of both IL1RL1 transcripts using RNAscope in two different in vivo models of neuroinflammation, experimental autoimmune encephalitis (EAE) and photothrombotic stroke. We present data showing that in rodents pericytes increase transcript expression predominantly for soluble IL1RL1 in inflammatory and stroke models. Our results highlight a novel expression pattern of the soluble and membrane bound forms of the IL-33 receptor in vitro and in combination with our observations in vivo suggest that cerebrovascular pericytes may negatively regulate IL-33 signalling following injury or inflammatory insults to the brain.

Indexed as

Central Nervous SystemInflammationInterleukin-1 Receptor-Like 1 ProteinPericytesAnimalsBecaplerminEncephalomyelitis, Autoimmune, ExperimentalHumansInterleukin-33RNA, MessengerSignal TransductionSolubilityBecaplerminIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinInterleukin-33RNA, MessengerIL1RL1IL-33IL-4PDGF-BBTGF-alpha

Identifiers

PMID41857656
PMCPMC13123163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.